CL AT 413
Alternative Names: CL-AT-413Latest Information Update: 28 Sep 2022
Price :
$50 *
At a glance
- Originator Charleston Laboratories
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA
- 07 Aug 2018 CL AT 413 is available for licensing in World as of 07 Aug 2018. https://charlestonlabs.com
- 07 Aug 2018 Preclinical trials in Respiratory tract disorders in USA (unspecified route) (Charleston Laboratories pipeline, August 2018)